| Page 435 | Kisaco Research

NeuChips Webinar - Case Study

Kisaco Research designed a comprehensive marketing strategy that included targeted email campaigns, social media promotion, and partnership outreach. The promotional assets featured engaging visuals and compelling content that highlighted the unique value proposition of NeuChips.

Read more about NeuChips Webinar - Case Study

Using Pharmaceutical Meta-Analytical Screening (PMAS) for Personalized Microbiome Solution

Considerations for live-biotherapeutic development and applicability: reviewing microbiota variation, biomarkers, and metabolites.
Integrating a personalization approach to therapeutic discovery, linking clinical trial outcomes with in-vitro results obtained from the PMAS system.
How to harness the metabolome to guide the next generation of live-biotherapeutics.

Yosep Ji, Chief Executive Officer, HEM Pharma

Author:

Yosep Ji

Chief Executive Officer

HEM Pharma

Read more about Using Pharmaceutical Meta-Analytical Screening (PMAS) for Personalized Microbiome Solution

Navigating Investment Challenges for Microbiome Drug Development: The Roadmap to Investment

Introduction to the current microbiome investment landscape and what direction investment is heading in over the next few years.
Highlighting what investors need to see from emerging companies, how are CSB evaluating companies.
How should microbiome companies adapt to trends and what should data packages contain.

Sou Miyake, Director of Investment & Business Development, Corundum Systems Biology